The Rx Assistant launches Builder, a no-code platform for pharma AI experiences

Nov 17, 2026
The Rx Assistant unveiled Builder at HLTH 2026, letting pharmaceutical brands deploy AI experiences for patients and healthcare professionals across voice, SMS, email and chat.

The Rx Assistant, an AI company that works with pharmaceutical brands on patient engagement, has unveiled Builder, a no-code platform that lets drug makers build, approve and deploy AI experiences for patients and healthcare professionals across voice, SMS, email and online chat. The company announced it at HLTH 2026.

Builder is the platform behind the company's existing AI concierge. It combines conversational AI with pharmaceutical regulatory workflows and analytics, and it automates regulatory review and adverse event logging and reporting to meet pharmacovigilance requirements. It connects to patient support platforms, pharmacy systems, medical records and CRM software.

The company reports its own results from deployments. Brands in early deployments moved from contract signing to approval in eight weeks, it says, and in existing deployments 75% of engaged users completed an action the brand had defined, such as finding a doctor or finishing a symptom quiz. The Rx Assistant also says its concierge beat the brand's own website by more than 3 to 1 on those actions. It did not name the brands.

"When a patient uses a chat, a quiz or a doctor finder, they're telling you they need help or are ready to take action," said Jake Coniglio, co-founder and CEO.

At the same event the company won the Digital Health Hub Foundation's Rising Star award in its therapeutics, pharmacy and medication category, according to the announcement. The Rx Assistant was founded by former leaders of GoodRx, One Medical and Epocrates and is backed by GoodRx and Suncoast Ventures.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly, Sales & Marketing AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.